Celebrating the great minds that bring us innovation in small molecules, biopharmaceuticals, and advanced medicine.
Gene therapy manufacturers will need to focus on upstream filtration to minimize the risk of viral infection.
How can manufacturers avoid frustrating and inadvertent changes to the solid forms of APIs?
Lives and livelihoods depend on accelerating large molecule drug production, so biopharma companies must minimize defects and contamination.
In December, The Medicine Maker will showcase the top technologies to have been released throughout 2020. Nominations are now open.
As the world grasps the severity of the ongoing pandemic, we must ask how we can accelerate vaccine development safely.
It is well accepted that vaccine development needs to move faster, but how can companies balance compliance and speed?
How are counterfeiters exploiting the COVID-19 pandemic to make a profit?
There are ample opportunities for pharma companies to transition to greener chemical processes. Martin Hayes from Johnson Matthey tells us more.
We need to optimize and then accelerate HPAPI drug product development. Alyn McNaughton from Lonza tells us more.
Advanced medicine companies are shifting their focus to off-the-shelf approaches, solid tumors, and combinations with immune checkpoint modulators.
Register to access our FREE online portfolio, request the magazine in print and
manage your preferences.